<DOC>
	<DOCNO>NCT03056690</DOCNO>
	<brief_summary>The purpose study assess analgesic efficacy ASP0819 relative placebo well safety tolerability . This study also assess treatment difference physical function well improvement overall subject status ( e.g. , fibromyalgia symptom global functioning ) ASP0819 relative placebo .</brief_summary>
	<brief_title>A Study Assess Analgesic Efficacy Safety ASP0819 Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Subject body mass index ( BMI ) ≤ 45 kg/m2 . Female subject must either : Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior Screening , document surgically sterile ( e.g. , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) . Or , childbearing potential : agree try become pregnant study 28 day final study drug administration , negative blood pregnancy test Screening negative urine test Day 1 , heterosexually active , agree consistently use 1 form highly effective birth control start Screening throughout study period 28 day final study drug administration . Female subject must agree breastfeed Screening throughout study period , 28 day final study drug administration . Female subject must donate ovum start Screening , throughout study period , 28 day final study drug administration Male subject must donate sperm start Screening throughout study period , 28 day final study drug administration . Male subject partner childbearing potential , pregnant breastfeeding partner ( ) must agree remain abstinent use condom throughout study period 28 day final study drug administration . Subject meet American College Rheumatology ( ACR ) 1990 fibromyalgia diagnostic criterion Screening : Widespread pain least 3 month , define presence follow : pain right leave side body , pain waist , pain axial skeleton ( cervical spine anterior chest thoracic spine low back ) must present . Pain least 11 18 tender point sit digital palpation . Digital palpation perform approximate force 4 kg . Subject meet ACR 2010 fibromyalgia diagnostic criterion Screening : Widespread pain index ( WPI ) ≥ 7 Symptom severity ( SS ) scale score ≥ 5 WPI 36 SS scale score ≥ 9 . Symptoms present similar level least 3 month . The subject disorder would otherwise explain pain . Subject pain score ≥ 4 revise fibromyalgia impact questionnaire revise ( FIQR ) pain item Screening . Subject compliant daily pain recording Baseline Diary RunIn period , define completion minimum 5 7 daily average pain rating agree complete daily diary throughout duration study . Subject mean daily average pain score ≥ 4 ≤ 9 11point 0 10 NRS record subject ediary Baseline Diary RunIn period , meet prespecified criterion daily average pain score . Subject agree use acetaminophen rescue medication fibromyalgia pain throughout course trial ( 1000 mg per dose exceed 3000 mg/day ) . Subject agrees initiate change nonpharmacologic intervention ( include normal daily exercise routine , chiropractic care , physical therapy , psychotherapy , massage therapy ) course study . Nonpharmacologic intervention must stable minimum 30 day prior Screening . The subject agree maintain usual level activity duration study . Subject capable completing study assessment procedure . Subject agree participate another interventional study Screening End Study ( EOS ) visit . Subject receive investigational therapy within 28 day 5 halflives , whichever longer , prior Screening . Subject meaningful improvement , 2 prior treatment ( commercially available ) fibromyalgia ( least 2 pharmacologic class ) . Subject know hypersensitivity intolerance use acetaminophen associate formulation component ; know hypersensitivity formulation component ASP0819 . Subject pain due diabetic peripheral neuropathy , postherpetic neuralgia , traumatic injury , prior surgery , complex regional pain syndrome , source pain would confound interfere assessment subject 's fibromyalgia pain require exclude therapy subject 's study participation . Subject infectious inflammatory arthritis ( e.g. , rheumatoid arthritis , ankylose spondylitis , psoriatic arthritis gout ) , autoimmune disease ( e.g. , systemic lupus erythematosus ) , widespread rheumatic disease fibromyalgia . Subject current , untreated moderate severe major depressive disorder assess MiniInternational Neuropsychiatric Interview ( M.I.N.I. ) . Subject current , treat major depressive disorder include provide without clinically significant change symptom dose protocol allow antidepressant great 60 day prior Screening . Subject initiated nonpharmacologic intervention treatment fibromyalgia depression within 30 day prior Screening Screening period . Subject history psychotic and/or bipolar disorder assess M.I.N.I . Subject Hospital Anxiety Depression Scale ( HADS ) score &gt; 14 Depression subscale Screening time Visit 3 ( Randomization ) . Subject history suicide attempt suicidal behavior within last 12 month , suicidal ideation within last 12 month ( response `` yes '' question 4 5 suicidal ideation portion ColumbiaSuicide Severity Rating Scale ( CSSRS ) ) , significant risk commit suicide time Visit 3 ( Randomization ) . Subject clinically significant abnormality clinical chemistry , hematology , urinalysis , serum creatinine &gt; 1.5 time Upper limit normal ( ULN ) Screening . These assessment may repeat , reasonable time period ( within Screening period ) . Subject aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥ 1.5 time upper limit reference range Screening . These assessment may repeat , reasonable time period ( within Screening period ) . Subject positive test hepatitis B surface antigen ( HBsAg ) , hepatitis A virus antibody ( immunoglobulin M ) ( antiHAV [ IgM ] ) hepatitis C virus antibody ( antiHCV ) Screening history positive test human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) . Subject rest systolic blood pressure ( SBP ) &gt; 180 mmHg &lt; 90 mmHg , and/or sit diastolic blood pressure ( DBP ) &gt; 100 mmHg Screening . These assessment may repeat , reasonable time period ( within Screening period ) . Subject clinically significant abnormality 12lead Electrocardiogram ( ECG ) Screening Visit 3 ( Randomization ) . If ECG abnormal , additional ECG carry . If also give abnormal result , subject must exclude . Subject history myocardial infarction ( within 6 month Screening ) , unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsade de pointes , structural heart disease family history Long time electrocardiogram Q wave end T wave ( QT ) Syndrome . Subject evidence clinically significant , uncontrolled cardiovascular , gastrointestinal , endocrinologic ( low thyroid stimulate hormone [ TSH ] , euthyroid allow ) , hematologic , hepatic , immunologic , infectious , metabolic , urologic , pulmonary ( include obstructive sleep apnea control Continuous positive airway pressure ( CPAP ) device ) neurologic , dermatologic , psychiatric , renal and/or major disease ( exclusive fibromyalgia ) . Subject plan surgery study participation . Subject active malignancy history malignancy ( except treat nonmelanoma skin cancer ) within 5 year Screening . Subject positive drug alcohol test Screening , Baseline Diary RunIn prior Randomization . However , positive test tetrahydrocannabinol ( THC ) and/or opioids allow Screening visit , must confirm negative prior Baseline Diary RunIn Randomization . Subject current recent ( within 12 month Screening ) history substance use disorder include cannabinoid and/or alcohol abuse disorder . Subject use opioids pain 4 day week precede Screening visit . Subject currently use protocol specify prohibited medication unable washout . Subject file await judgment disability claim pending worker 's compensation litigation relate monetary settlement . Subject employee Astellas Group , Contract Research Organization ( CRO ) involve , investigator site personnel directly affiliate study and/or immediate family ( spouse , parent , child , sibling , whether biological legally adopt ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ASP0819</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>